Volume 2.42 | Nov 18

Prostate Cell News 2.42, November 18, 2011
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Pim Kinase Inhibitors Sensitize Prostate Cancer Cells to Apoptosis Triggered by Bcl-2 Family Inhibitor ABT-737
Since overexpression of Bcl-2 family members are implicated in chemotherapeutic resistance in prostate cancer, researchers investigated the cooperative effects of Pim kinase inhibition with ABT-737, a small molecule antagonist of Bcl-2 family members. [Cancer Res] Abstract

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by Impact Factor of the Journal)

An Artificial PAP Gene Breaks Self-Tolerance and Promotes Tumor Regression in the Transgenic Adenocarcinoma of the Mouse Prostate Model for Prostate Carcinoma
In this study, researchers present a DNA vaccine encoding for the prostate-specific antigen prostatic acid phosphatase (PAP) linked to the J-domain and the SV40 enhancer sequence. [Mol Ther] Abstract

Cannabinoid Receptor Type 1 (CB1) Activation Inhibits Small GTPase RhoA Activity and Regulates Motility of Prostate Carcinoma Cells
In this study, researchers examined the molecular mechanisms that diminish cell migration upon the CB1 activation in prostate carcinoma cells. [Endocrinology] Abstract

Tumor Suppressors miR-1 and miR-133a Target the Oncogenic Function of Purine Nucleoside Phosphorylase (PNP) in Prostate Cancer
Researchers examined the functional significance of miR-1 and miR-133a in prostate cancer cells and identified the novel molecular targets regulated by both miR-1 and miR-133a. [Br J Cancer] Abstract

Identification of Markers of Prostate Cancer Progression Using Candidate Gene Expression
The aim of this study was to identify markers associated with the progression of prostate cancer. [Br J Cancer] Abstract

Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression
Here researchers report the use of the c-Myc adenocarcinoma cell line from the c-Myc transgenic mouse with prostate cancer to evaluate the in vitro and in vivo anti-tumor activity of the combination of the Histone Deacetylases (HDACs) inhibitor panobinostat with the Mammalian Target of Rapamycin Complex 1 (mTORC1) inhibitor everolimus. [PLoS One] Abstract

The Gap Junction Protein Cx43 Is Involved in the Bone-Targeted Metastatic Behavior of Human Prostate Cancer Cells
Researchers investigated the effect of the increased connexin43 (Cx43) expression, by retroviral infection, on the metastatic behavior of two well-characterized cell lines (PC-3 and LNCaP) representing different stages of prostate cancer progression. [Clin Exp Metastasis] Abstract

SLUG Promotes Prostate Cancer Cell Migration and Invasion via CXCR4/CXCL12 Axis
Researchers provide the first compelling evidence that upregulation of autocrine CXCL12 is a major mechanism underlying SLUG-mediated migration and invasion of prostate cancer cells. [Mol Cancer] Abstract

Role and Expression of FRS2 and FRS3 in Prostate Cancer
Here researchers investigated FGF receptor substrates (FRS2 and FRS3) as a means of disrupting global FGF signaling in prostate cancer. [BMC Cancer] Abstract


Denosumab and Bone-Metastasis-Free Survival in Men with Castration-Resistant Prostate Cancer: Results of a Phase III, Randomized, Placebo-Controlled Trial
Researchers assessed denosumab, a fully human anti-RANKL monoclonal antibody, for prevention of bone metastasis or death in non-metastatic castration-resistant prostate cancer. [Lancet] Abstract

Beta-Carotene Antioxidant Use during Radiation Therapy and Prostate Cancer Outcome in the Physicians’ Health Study
Researchers performed a prospective study nested within the Physicians’ Health Study randomized trial to determine if supplemental antioxidant use during radiation therapy for prostate cancer is associated with an increased risk of prostate cancer death or metastases. [Int J Radiat Oncol Biol Phys] Abstract

High Dose Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer
Researchers evaluated their retrospective, single institution experience with high dose rate brachytherapy as monotherapy for intermediate risk prostate cancer. [J Urol] Abstract

Evaluation of Glutathione-S-Transferase P1 and Adenomatous Polyposis Coli Methylation as Indicators for Repeat Biopsy in a High-Risk Cohort of Men with Negative Initial Prostate Biopsies
The objective of this study was to evaluate the performance of DNA methylation biomarkers in the setting of repeat biopsy in men with an initially negative prostate biopsy but a high index of suspicion for missed prostate cancer. [BJU Int] Abstract | Press Release

Do Your Colleagues Know What They Are Missing? Share This Newsletter Now

Halozyme’s Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase II Study Results
Data from the Phase II study indicated that the Company’s recombinant human hyaluronidase enzyme reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72nd Scientific Sessions, Philadelphia] Press Release

Interim Data From Pre-administration of Hylenex in Analog Insulin Pump Therapy Demonstrate Consistent Insulin Action Profile
Halozyme Therapeutics, Inc. presented results from a Phase IV study of Hylenex® recombinant (hyaluronidase human injection) in sensor augmented insulin analog pump (SAP) therapy in patients living with Type 1 diabetes. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72nd Scientific Sessions, Philadelphia] Press Release

Stem Cell Society Singapore (SCSS) 2012 Symposium: Stem Cell Based Therapy


GSU Researcher Receives Grant to Explore Sweeter, Greener Ways to Naturally Fight Cancer
The American Cancer Society has awarded a $720,000 grant to a Georgia State University (GSU) scientist to explore the cancer preventing benefits of sweet potato greens in prostate cancer. [Georgia State University] Press Release

Oklahoma’s Tobacco Settlement Endowment Fund to Support Cancer Research at Stephenson Cancer Center and Affiliated Research Institutions
The Peggy and Charles Stephenson Cancer Center at the University of Oklahoma Health Sciences Center has received the largest grant in its history – a five-year, $30 million grant – from the Oklahoma Tobacco Settlement Endowment Trust to help translate promising research into new and more effective cancer treatments and diagnostic tools. [The University of Oklahoma Health Sciences Center] Press Release

Cancer Immunotherapy Consortium Appoints New Leadership
The Cancer Research Institute (CRI), Inc. announced that James P. Allison, Ph.D., chair of the immunology program at Memorial Sloan-Kettering Cancer Center, and Axel Hoos, M.D., Ph.D., medical lead in immunology/oncology at Bristol-Myers Squibb, have been named directors of the CRI Cancer Immunotherapy Consortium. [Cancer Research Institute] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW American Association for Cancer Research – Noncoding RNAs and Cancer 
January 8-11, 2012
Miami Beach, United States

Visit our events page to see a complete list of events in the prostate cell community.

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Research Associate – Development (Precision Therapeutics, Inc.) 

Postdoc – Prostate Cancer (Weill Cornell Medical College)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us